Ocuphire Pharma Results

Opportunities for New Therapies in Retina Unmet Needs in Retina Especially in NPDR New MOAs/therapies are needed to: Provide non-invasive options for early disease management Decrease in Diabetic Retinopathy Severity Score (DRSS) Ocuphire ● PHARMA ● ● ● ● ● ● ● APX3330 offers: ● Decrease in macular edema Reduce vision threatening complications (VTC) ● Improve in macular ischemia Improve compliance by longer acting drugs Manage inflammation Address non-responders A novel, dual MOA A novel and non-invasive route, where oral medication allows for early intervention 30

View entire presentation